Skip to main content
Clinical Trials/NCT05692752
NCT05692752CompletedNot Applicable

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction Egyptian Patients

Islamia University of Bahawalpur1 site in 1 country10 target enrollmentStarted: December 28, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
10
Locations
1
Primary Endpoint
Expression of miR-208b

Study Overview

Brief Summary

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Detailed Description

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, > 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated.

Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
35 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients diagnosed with ST-Elevated Myocardial Infarction will be identified at the Coronary Care Unit at Ain-shams University hospital
  • •Acute episode of Myocardial Infarction
  • •With No history of previous Myocardial Infarction Treatment

Exclusion Criteria

  • •Patients not diagnosed with ST-Elevated Myocardial Infarction and healthy at the Coronary Care Unit at Ain-shams
  • •University hospital
  • •Previously Known patients of Myocardial infacrtion
  • •Previous medication

Outcomes

Primary Outcomes

Expression of miR-208b

Time Frame: 48 hours from the onset of the infarct

Expression during episodes of myocardial infarction

Expression of miR-133a

Time Frame: 48 hours from the onset of the infarct

Expression during episodes of myocardial infarction

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Islamia University of Bahawalpur
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hafiz Abdul Sattar Hashmi

Lecturer

Islamia University of Bahawalpur

Study Sites (1)

Loading locations...

Similar Trials